Candida Glabrata

Common Name(s)

Candida Glabrata

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Candida Glabrata" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Candida Glabrata" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Candida Glabrata" returned 206 free, full-text research articles on human participants. First 3 results:

Generational distribution of a Candida glabrata population: Resilient old cells prevail, while younger cells dominate in the vulnerable host.
 

Author(s): Tejas Bouklas, Luz Alonso-Crisóstomo, Tamás Székely, Elizabeth Diago-Navarro, Erika P Orner, Kalie Smith, Mansa A Munshi, Maurizio Del Poeta, Gábor Balázsi, Bettina C Fries

Journal:

 

Similar to other yeasts, the human pathogen Candida glabrata ages when it undergoes asymmetric, finite cell divisions, which determines its replicative lifespan. We sought to investigate if and how aging changes resilience of C. glabrata populations in the host environment. Our data ...

Last Updated: 10 May 2017

Go To URL
Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds.
 

Author(s): W A Schell, A M Jones, E P Garvey, W J Hoekstra, R J Schotzinger, B D Alexander

Journal:

 

The in vitro activities of fungal CYP51 inhibitors VT-1161 and VT-1129 were determined for Candida glabrata (n = 34) and C. krusei (n = 50). C. glabrata isolates were screened for FKS gene mutations. All isolates were resistant clinically and/or in vitro to at least one standard antifungal ...

Last Updated: 13 Dec 2016

Go To URL
In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
 

Author(s): María Ángeles Bordallo-Cardona, Pilar Escribano, Elia Gómez G de la Pedrosa, Laura Judith Marcos-Zambrano, Rafael Cantón, Emilio Bouza, Jesús Guinea

Journal:

 

We assessed the in vitro susceptibility of five echinocandin-susceptible Candida glabrata isolates after exposure to micafungin. The direct exposure to plates at different micafungin concentrations resulted in the inhibition of growth at 0.062 μg/ml. The progressive exposure was ...

Last Updated: 22 Nov 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Candida Glabrata" returned 7 free, full-text review articles on human participants. First 3 results:

Candida glabrata: new tools and technologies-expanding the toolkit.
 

Author(s): Hsueh-lui Ho, Ken Haynes

Journal: FEMS Yeast Res.. 2015 Sep;15(6):.

 

In recent years, there has been a noticeable rise in fungal infections related to non-albicans Candida species, including Candida glabrata which has both intrinsic resistance to and commonly acquired resistance to azole antifungals. Phylogenetically, C. glabrata is more closely related ...

Last Updated: 18 Aug 2015

Go To URL
Candida glabrata: a deadly companion?
 

Author(s): Monique Bolotin-Fukuhara, Cécile Fairhead

Journal: Yeast. 2014 Aug;31(8):279-88.

 

The yeast Candida glabrata has become a major fungal opportunistic pathogen of humans since the 1980s. Contrary to what its name suggests, it is much closer, phylogenetically, to the model yeast Saccharomyces cerevisiae than to the most prevalent human fungal pathogen, Candida albicans. ...

Last Updated: 18 Aug 2014

Go To URL
Arteriovenous graft infection caused by Candida glabrata: A case report and literature review.
 

Author(s): Hung-Ling Huang, Chun-Yu Lin, Ya-Ting Chang, Yen-Hsu Chen, Wei-Tsung Wu, Po-Liang Lu

Journal: J Microbiol Immunol Infect. 2016 Apr;49(2):300-4.

 

The infection rate of arteriovenous (AV) grafts is high, but fungal etiology is rare. Only five cases of graft infection due to Candida albicans (C. albicans) or C. tropicalis have been described in the literature. Herein, we report the first case of AV graft infection caused by C. ...

Last Updated: 26 Mar 2016

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.